Estrone
(Synonyms: 雌酮; E1; Oestrone) 目录号 : GC14385
Estrone是三种主要的内源性雌激素之一，其他是雌二醇和雌三醇。
Cas No.:53-16-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Estrone is one of the three major endogenous estrogens, the others being estradiol and estriol[1]. Estrone is synthesized from cholesterol and is primarily secreted by the gonads, but can also be formed by adrenal androgens in adipose tissue[2]. Estrone is an agonist of the estrogen receptor[3]. Estrone can effectively activate multiple signaling and functional responses in pituitary cells at low physiological concentrations[4].
In vitro, treatment of human endothelial colony-forming cells (hECFCs) with Estrone (0-1µM) for 24h significantly promoted cell proliferation at concentrations of 1nM and 10nM, and inhibited proliferation at a concentration of 1µM[5]. Treatment of bone progenitor cells with Estrone (10nM) upregulated the expression of estrogen receptor α (ER-α) and estrogen receptor β (ER-β), but downregulated the expression of osteopontin (OPN)[6]. Estrone (10-3-105nM) treated mouse colon cancer MC38 cells for 24-72h inhibited cell growth in a dose- and time-dependent manner[7].
In vivo, subcutaneous injection of Estrone (0.5mg/kg) in rats with traumatic brain injury reduced cortical lesion volume and neuronal damage, reduced the level of TUNEL-positive staining in the cerebral cortex, reduced the number of TUNEL-positive cells in the corpus callosum, and reduced the cortical level of β-amyloid protein after brain injury[8].
References:
[1] Bennink H J T C. Are all estrogens the same?[J]. Maturitas, 2004, 47(4): 269-275.
[2] Tchernof A, Mansour M F, Pelletier M, et al. Updated survey of the steroid-converting enzymes in human adipose tissues[J]. The Journal of steroid biochemistry and molecular biology, 2015, 147: 56-69.
[3] Eyster K M. The estrogen receptors: an overview from different perspectives[J]. Estrogen Receptors: Methods and Protocols, 2016: 1-10.
[4] Watson C S, Jeng Y J, Kochukov M Y. Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation[J]. The FASEB Journal, 2008, 22(9): 3328.
[5] Ivory A, Greene A S. Distinct roles of estrone and estradiol in endothelial colony‐forming cells[J]. Physiological Reports, 2023, 11(19): e15818.
[6] Park J B. Effects of low doses of estrone on the proliferation, differentiation and mineralization of osteoprecursor cells[J]. Experimental and Therapeutic Medicine, 2012, 4(4): 681-684.
[7] Motylewska E, Mełeń-Mucha G. Estrone and progesterone inhibit the growth of murine MC38 colon cancer line[J]. The Journal of steroid biochemistry and molecular biology, 2009, 113(1-2): 75-79.
[8] Gatson J W, Liu M M, Abdelfattah K, et al. Estrone is neuroprotective in rats after traumatic brain injury[J]. Journal of neurotrauma, 2012, 29(12): 2209-2219.
Estrone是三种主要的内源性雌激素之一，其他是雌二醇和雌三醇[1]。Estrone是由胆固醇合成的，主要由性腺分泌，也可以由脂肪组织中的肾上腺雄激素形成[2]。Estrone是雌激素受体的激动剂[3]。Estrone在低生理浓度下能够有效地激活垂体细胞中的多种信号传导和功能反应[4]。
在体外，Estrone（0-1µM）处理人内皮集落形成细胞（hECFCs）细胞24h，在1nM和10nM浓度下显著促进了细胞增殖，1µM的浓度下抑制了增殖[5]。Estrone（10nM）处理骨前体细胞，上调了雌激素受体α（ER-α）和雌激素受体β（ER-β）的表达，但下调了骨桥蛋白（OPN）的表达[6]。Estrone（10-3-105nM）处理小鼠结肠癌MC38细胞24-72h，以剂量和时间依赖性方式抑制了细胞的生长[7]。
在体内，Estrone（0.5mg/kg）通过皮下注射治疗创伤性脑损伤大鼠，减少了皮质病变体积和神经元损伤，降低了大脑皮层TUNEL阳性染色的水平，减少了胼胝体中TUNEL阳性细胞的数量，降低了脑损伤后β-淀粉样蛋白的皮质水平[8]。
| Cell experiment [1]: | |
|
Cell lines |
Human endothelial colony-forming cells (hECFCs) |
|
Preparation Method |
5×104 serum starved hECFCs were seeded into 24 wells plates and incubated with IncuCyte® NucLight Rapid Red Reagent for nuclear labeling. Celprogen media with serum and antibiotics was supplemented with the desired treatment. Treatment groups included: Estrone, estradiol, or 1 to 1 ratio combination of Estrone/estradiol at 0nM (medium control), 1nM, 10nM, 100nM, and 1µM. The hECFCs were then incubated for 24h during which the cells were imaged in the IncuCyte SX5 Live-Cell Analysis System (Sartorius). Cell number was then quantified and presented as percentage of control. |
|
Reaction Conditions |
1nM, 10nM, 100nM, 1µM; 24h |
|
Applications |
The effect of Estrone on hECFC proliferation was biphasic with only exposures of 1nM and 10nM resulting in significant increases in hECFC proliferation. Estrone exposure at 1μM resulted in attenuated proliferation and resulted in a significantly lower hECFC cell number than control. |
| Animal experiment [2]: | |
|
Animal models |
Sprague-Dawley rats |
|
Preparation Method |
The Benchmark Stereotaxic Impactor was used to administer severe TBI in rats. An incision was made to expose the skull, and the craniotomy procedure was performed. Following the craniotomy procedure, a cortical contusion was delivered to the right hemisphere via a vertically-directed pneumatic cylinder. The skin was closed with surgical wound clips. At 30min following brain injury, the animals were treated subcutaneously with Estrone (0.5mg/kg) or vehicle (corn oil). Control and sham (craniotomy only) animals were also included as controls. The animals were monitored for pain every 6h for the first 24h, and once a day thereafter. At 72h following injury, the animals were perfusedintracardially with 0.9% saline followed by 10% phosphate-buffered formalin. The whole brain was removed, sliced, and stained for TUNEL-positive cells. |
|
Dosage form |
0.5mg/kg; s.c. |
|
Applications |
Estrone decreased cortical lesion volume and neuronal injury, and it reduced cerebral cortical levels of TUNEL-positive staining, and decreased numbers of TUNEL-positive cells in the corpus callosum. |
|
References: |
|
| Cas No. | 53-16-7 | SDF | |
| 别名 | 雌酮; E1; Oestrone | ||
| 化学名 | (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one | ||
| Canonical SMILES | CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O | ||
| 分子式 | C18H22O2 | 分子量 | 270.37 |
| 溶解度 | ≥ 9.75 mg/mL in DMSO, ≥ 9.2 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6986 mL | 18.4932 mL | 36.9864 mL |
| 5 mM | 0.7397 mL | 3.6986 mL | 7.3973 mL |
| 10 mM | 0.3699 mL | 1.8493 mL | 3.6986 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet